GTx Closer To Filing NDA For Acapodene With Promising Phase III Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Findings of reduced vertebral fracture risk mean drug could offer 39-month median survival improvement, company tells DAILY.
You may also be interested in...
Amgen’s Denosumab, GTx’s Toremifene Keep Pace At ASCO On Prevention Of Bone Fractures In Prostate Cancer Patients
Both firms have October user fee dates for prevention of bone fracture risk in prostate cancer patients on androgen deprivation therapy, and both report favorable incremental data.
Amgen’s Denosumab, GTx’s Toremifene Keep Pace At ASCO On Prevention Of Bone Fractures In Prostate Cancer Patients
Both firms have October user fee dates for prevention of bone fracture risk in prostate cancer patients on androgen deprivation therapy, and both report favorable incremental data.
GTx Continues Phase III For Toremifene 20 Mg With Goal Of 2009 NDA
Bar is lower for meeting primary efficacy endpoint at trial’s end than for interim data review, firm tells “The Pink Sheet” DAILY.